micro-community-banner
 
  • Saved

2mo
case study

Patient Background:

A 23-year-old woman with childhood-onset Moyamoya disease presented with recurrent seizures and a history of cerebrovascular events. At age 5, she experienced focal motor seizures, initially misattributed to psychogenic causes. By age 7, she developed acute right-sided weakness and aphasia, resulting in residual facial palsy and partial aphasia.

By 2023, exam findings included asthenic habitus, venous insufficiency, mild cognitive impairment (MMSE 26), hyperreflexia (right > left), distal right arm weakness, prosopagnosia, and severe myopia.

Assessment & Diagnosis:

An MRI from 2005 revealed right hemisphere atrophy. In 2006, cerebral angiography confirmed Moyamoya disease, with bilateral carotid artery occlusions and collateral “puff of smoke” vessels. Repeat MRI in 2023 demonstrated chronic ischemic lesions, and angiography confirmed diminished anterior circulation with compensatory collaterals. EEG revealed right-sided background slowing and left temporoparietal epileptiform discharges, consistent with focal seizures. Neuropsychological testing showed mild cognitive disorder with visual–spatial deficits and agnosia.

  1. How is seizure control balanced with stroke prevention in Moyamoya disease?
  2. When is revascularization considered in Moyamoya with seizures, and how is perioperative seizure risk managed?
  • Saved

2mo
Mental Health Experiences and Challenges Among Individuals with Myasthenia Gravis: Insights from Patient-Centered, Qualitative Analyses - PubMed

Mental Health Experiences and Challenges Among Individuals with Myasthenia Gravis: Insights from Patient-Centered, Qualitative Analyses - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41123841/

This qualitative, hypothesis-generating study found that individuals with MG in the US were more likely to report experiencing anxiety and depression than the general population due, at least in part,...

This qualitative study highlights high rates of anxiety and depression in myasthenia gravis, identifying stressors linked to symptom burden, care demands, and social challenges that exacerbate psychological distress throughout the disease journey.

  • Saved

3mo
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The 2025 annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) spans four days and is taking place in San Francisco, along with an option to participate virtually. The meeting brings physicians, technologists, advanced practice providers, and other health care professionals together to learn about the latest advances in neuromuscular medicine, electrodiagnostic medicine, neuromuscular ultrasound, and more, with presentations and posters covering the influx of new therapies and technologies.

Click above to access a full summary of sessions so far.

  • Saved

3mo
Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia-Pacific - PubMed

Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia-Pacific - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41131267/

Across the Asia-Pacific, most patients did not achieve pharmacological remission despite prescribed treatments, and experienced treatment-related AEs, indicating significant unmet clinical needs. It is suggested that corticosteroid overreliance in maintenance...

A cross-sectional real-world survey across six Asia-Pacific countries found high disease burden in gMG patients, with most not achieving remission and experiencing corticosteroid-related adverse events, underscoring unmet therapeutic needs.

  • Saved

3mo
Functional Neurological Disorder: Advancing Diagnosis and Care for a Complex Neuropsychiatric Condition.

Functional neurological disorder (FND) is a disabling neuropsychiatric condition characterized by involuntary motor, sensory, or cognitive symptoms that are not explained by identifiable structural pathology. Once considered purely psychogenic, FND is now increasingly understood as a condition involving abnormal brain network connectivity and shaped by biopsychosocial factors.

Highlights:

  • FND is the second most common diagnosis in outpatient neurology, disproportionately affecting women and often emerging in early adulthood.
  • Neuroimaging studies reveal altered connectivity in circuits governing emotion, motor control, and self-agency, supporting FND as a genuine brain-based disorder.
  • Symptoms may include functional tremors, gait impairment, non-dermatomal sensory changes, and cognitive difficulties that do not align with classical neurological patterns.
  • Diagnosis increasingly focuses on “positive signs” of internal inconsistency and incongruence during neurologic examination, rather than exclusion of other diseases.
  • Optimal management requires a multidisciplinary approach—including neurology, psychiatry, psychology, and rehabilitation medicine.
  • Emerging predictive imaging techniques may enable future personalization of treatment strategies.

What sets this study apart:

This review underscores the evolution in how FND is diagnosed and treated—shifting from misdiagnosis and stigma toward evidence-based, multidisciplinary care. It highlights the need for early recognition, tailored interventions, and the continued development of objective diagnostic tools.

Limitations:

Challenges remain, including diagnostic uncertainty, persistent stigma, and the absence of standardized imaging protocols or individualized treatment pathways based on neurobiological profiles.

What role could predictive imaging play in guiding individualized treatment plans for FND?